RESET for Remission reported diabetes remission and preserved muscle at 24 weeks. We examine the supervised program, side effects and evidence limits.
On October 6, 2026, the University of Leicester reported results from the RESET for Remission trial, which paired a very-low-calorie diet with structured exercise for adults with early-onset type 2 diabetes. The reported findings included diabetes remission and fat loss alongside preserved muscle mass.
According to the University of Leicester’s account, the trial enrolled 96 adults with obesity who were not using insulin. Participants were aged 18 to 45 and had a mean age of 38. The randomized study took place across three centres in England and Canada.
The university describes early-onset type 2 diabetes as a distinct clinical pattern associated with rapidly worsening blood-sugar control and early complications. That concern provided the rationale for testing an intensive intervention rather than offering general lifestyle advice alone.
For readers interested in metabolic health, the important question is not simply whether participants lost weight. It is whether blood-sugar control improved while muscle and physical capacity were maintained. This study placed those outcomes alongside one another.
The intervention addressed food intake and exercise together. In the university’s account, participants followed an 800-900-calorie-per-day diet with structured exercise for 12 weeks. They then moved to a weight-maintenance plan with continued exercise for another 12 weeks.
The diet began with meal replacements and later allowed one regular meal a day. Exercise included supervision, while medication changes were made where appropriate. The comparison group received usual care.
The clearest way to understand the metabolic findings is to separate the outcomes being measured. Blood sugar describes glucose control. Fat mass and muscle mass describe body composition. Strength and fitness add information about physical capacity that a scale reading does not provide.
In the university’s report, improved blood-sugar control occurred alongside a reduction in fat mass and preservation of MRI-assessed muscle mass. Strength and fitness also increased. This describes a coordinated set of changes rather than evidence of a single biological switch.
That distinction matters when interpreting weight loss. A lower body weight does not identify which tissue changed or describe how someone performs physically. The trial’s body-composition measurements therefore add information beyond its weight-loss result.
Our guide to looking beyond scale weight provides context for understanding these different measures. The useful principle here is to evaluate metabolic health and physical capacity together rather than treating every reduction on the scale as the same outcome.
The University of Leicester’s headline used the word “reverses” to describe the diabetes findings. Medscape’s coverage used the more cautious wording “may drive” diabetes into remission. Both draw attention to the blood-sugar result, but remission is the more precise term for the defined outcome reported in this trial.
The broader phrase “diet and exercise” also leaves out important context. This was an intensive program involving meal replacements and supervised activity. It included structured support and clinical management rather than a request for participants to eat less and move more on their own.
Medscape identifies a central design limitation: there was no additional group receiving the diet without exercise. The trial therefore assessed the combined program against usual care. It did not establish how much dietary restriction or exercise independently contributed to remission or muscle preservation.
The study was also small and open-label, meaning participants and those delivering the intervention knew which treatment was being received. Endpoint assessment was blinded, so the people assessing the study outcomes did not know the assigned group. Those design features belong in the interpretation alongside the encouraging results.
The participant group also sets boundaries around the findings. These results do not establish the same remission rate for older adults or people without obesity. Nor do they establish that rate for people with different treatment histories, including those using insulin.
The university summary does not provide a complete exercise schedule. It would therefore be inappropriate to turn this report into a specific workout routine. The defensible conclusion concerns a supervised combined intervention, not a particular exercise prescription.
This distinction also keeps the discussion free of blame. The program changed nutrition and exercise support alongside clinical management. Those are features of treatment and environment, not measures of someone’s character or commitment.
The University of Leicester reports that remission at 24 weeks occurred in 54% of the intervention group compared with 4% of the usual-care group. Remission meant blood sugar below the diabetes threshold without diabetes medication for at least three months.
That definition matters because the outcome was not simply weight loss or an improvement in a blood test while treatment continued unchanged. Medication status and the period below the diabetes threshold were part of the assessment. The result should stay attached to that definition whenever the remission figure is discussed.
According to the university, the intervention group lost about 7.5 kg more than the usual-care group. That is a difference between groups, not the intervention group’s total weight loss. The report says most of the weight lost came from fat mass.
MRI-assessed muscle mass was preserved while strength and fitness increased. These are related but distinct findings: muscle measurement describes tissue quantity, while strength and fitness describe aspects of performance. Reporting them together gives a fuller picture of the intervention’s effects.
For readers concerned about body composition, this is the study’s most useful shift in emphasis. Success was assessed through more than a smaller body size. Our resource on nutrition and muscle retention during weight loss addresses that broader topic without turning this trial’s intensive diet into a general recommendation.
The University of Leicester reports that nine in ten participants completed the study. It also says most participants in the intervention group experienced at least one adverse event. Reported symptoms included constipation, headache, dizziness and fatigue.
The university says those symptoms resolved and that no severe adverse events were reported. Both parts deserve attention: the absence of reported severe events does not make the temporary symptoms irrelevant. A treatment’s burden matters alongside its benefits.
These findings are not instructions to attempt a very-low-calorie diet or stop diabetes medication. The intervention included clinical oversight and medication changes where appropriate. Anyone considering major dietary changes or medication adjustments should discuss them with their healthcare team.
A useful conversation would cover how blood sugar and medication use would be monitored alongside body composition and physical capacity. It should also address the support available during both weight loss and maintenance. Those questions reflect the program that was studied more accurately than asking only how quickly weight might fall.
The next question is whether the reported benefits last. Medscape notes that the 24-week findings do not establish whether remission or muscle preservation persisted over the longer term. Follow-up needs to track those outcomes together rather than following body weight alone.
Maintenance also deserves attention as an active part of treatment. In Medscape’s coverage, commentator Juleen Zierath emphasized planning for the period after the intensive phase. RESET for Remission included a maintenance phase, making that transition part of the intervention rather than an afterthought.
Future research should test the combined approach in larger and more varied populations. A diet-only comparison would help clarify the contribution of exercise. Studies in routine care should also examine whether services can provide the supervision and ongoing support used in the trial.
The evidence to watch next is sustained remission alongside preserved muscle and physical capacity under conditions that healthcare services can realistically deliver. That is what would help determine whether this approach should become standard practice. For now, RESET for Remission offers a promising result for a defined group and a useful standard for judging future research: assess what changes in the body and how those changes are supported over time.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
